A Phase 3 interventional study of Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free and Vehicle in Ocular Hyperemia, sponsored by Alcon Research. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.
Among the 23 studies in Hyperemia with a site in United States, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 3, and was the 22nd registered.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
Browse Hyperemia studies →9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 18+
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Sites in United States
Ages 18–65 · Healthy volunteers
Georgia State University · Sites in United States
Ages 20–59
Georgia State University · Sites in United States
Ages 20–65 · Women only
Georgia State University · Sites in United States
Ages 45–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 178 is above the median of 68 across 51 interventional studies indexed under Hyperemia.
Median enrollment 68 across the 19 interventional studies, 40 across the 4 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Alcon has 2 studies filed under Hyperemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07578363Phase 3Alcon ResearchAn Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | 2026-11 |
| NCT07531043Phase 3Alcon ResearchEfficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | 2027-02 |
| NCT07209410Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma | 2026-12-15 |
| NCT06735599Georgia State UniversityWild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure | 2027-01-01 |
| NCT06735651Georgia State UniversityWild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies in Hyperemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.
Eligible subjects will be expected to attend a total of 6 in-office study visits over a period of approximately 10 weeks. Subjects will receive a single dose of study treatment in each eye (either Apraclonidine 0.125% UDPF or Vehicle) on Day 1, after which subjects will be instructed to self-administer one drop in each eye twice daily at home for a total of approximately 8 weeks (Days 2-55), with the last dose administered on Day 56 in office. Subjects will then return for the final study visit on Day 63, following a 1-week treatment discontinuation. Eye redness will be assessed before and after instillation at prespecified timepoints.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop in each eye on Day 1, followed by one drop in each eye twice daily (approximately 12 hours apart, but not less than 11.5 hours apart) beginning the day following Day 1 up until the day prior to Day 56. On the day of Day 56, subjects will receive the last dose in-office.
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free
One drop in each eye on Day 1, followed by one drop in each eye twice daily (approximately 12 hours apart, but not less than 11.5 hours apart) beginning the day following Day 1 up until the day prior to Day 56. On the day of Day 56, subjects will receive the last dose in-office.
Drug: Vehicle
Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free formulation
Also known as: FID 123472, Apraclonidine 0.125% UDPF
Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free formulation
Change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity). This is a co-primary endpoint.
Time frame: Baseline (Day 1 pretreatment); 15 minutes post-instillation (Day 1)
Change from baseline in investigator-assessed ocular redness at 600 minutes post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity). This is a co-primary endpoint.
Time frame: Baseline (Day 1 pretreatment); 600 minutes post-instillation (Day 1)
Change from baseline in investigator-assessed ocular redness at 1 minute post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).
Time frame: Baseline (Day 1 pretreatment); 1 minute post-instillation (Day 1)
Change from baseline in investigator-assessed ocular redness at 720 minutes post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).
Time frame: Baseline (Day 1 pretreatment); 720 minutes post-instillation (Day 1)
Change from baseline in investigator-assessed ocular redness at 30 seconds post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).
Time frame: Baseline (Day 1 pretreatment); 30 seconds post-instillation (Day 1)
Number of subjects who achieve prespecified improvements from baseline in investigator-assessed ocular redness score in both eyes at 30 seconds post-instillation on Day 1
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). The 30-second score will be compared to the baseline score. The number of subjects with improvements as prespecified in the protocol will be reported.
Time frame: Baseline (Day 1 pretreatment); 30 seconds post-instillation (Day 1)
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Nov 2026 and completion Mar 2027 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.